Key Takeaways
- An EPO-QMP albumin fusion lasted 5.7 days in engineered mice, versus 1.1 days for EPO fused to ordinary albumin.
- QMP has three amino-acid changes and binds the FcRn recycling receptor about 180 times more strongly.
- Nasal dosing delivered five times more QMP fusion into circulation in mice, but no human has received it.
A blood medicine that vanishes in hours
Erythropoietin — EPO — stimulates the body to make red blood cells, and recombinant versions are used to treat anemia associated with chronic kidney disease and some treatments, including chemotherapy. The problem is staying power: early recombinant EPO products have a plasma half-life of 4–11 hours after intravenous administration in humans, rising to about a day after subcutaneous administration. Patients may therefore receive injections up to several times a week.
Three tiny edits to a workhorse protein
Researchers tried a different fix: attach EPO to albumin, the blood protein that normally survives about three weeks because a recycling receptor called FcRn keeps rescuing it from destruction. Their engineered albumin variant, nicknamed QMP, carries three amino-acid changes — yet has been shown to bind that recycling receptor about 180 times more strongly under the acidic conditions where binding occurs.
Five times longer in the blood
In mice engineered to carry the human version of the recycling receptor, the difference was stark. After intravenous administration, EPO fused to QMP had a 5.2-fold longer plasma half-life than EPO fused to ordinary albumin. Both fusions bound the EPO receptor with kinetics equal to those of darbepoetin alfa, a commercial EPO product. Mice given EPO-QMP also had a more prolonged increase in erythrocytes than mice given darbepoetin alfa.
The nose knows
Delivery was also tested through the nose. Intranasal administration produced circulating EPO-QMP and a prolonged increase in erythrocytes compared with darbepoetin alfa. Delivering complex proteins across mucosal barriers such as the nose or lungs is normally hampered by poor uptake and delivery to blood and tissue. The FcRn-targeted carrier offers a potential route for non-invasive delivery.
The honest part
These are mouse data from animals engineered to express human FcRn. They do not establish how the fusion would perform in people. The authors describe EPO-QMP as a design to explore for invasive and non-invasive delivery to patients with anemia.
The Twikup Take
Most drug innovation chases new molecules. This team instead re-engineered the carrier attached to EPO. The mouse findings suggest that FcRn-targeted albumin could be explored as a way to extend the circulation time of protein medicines while supporting delivery across mucosal surfaces.
Image: AI-generated illustration.